| Literature DB >> 33407605 |
Paolo A Ascierto1, Lisa H Butterfield2, Katie Campbell2, Bruno Daniele3, Michael Dougan4, Leisha A Emens5, Silvia Formenti6, Filip Janku7, Samir N Khleif8, Tomas Kirchhoff9, Alessandro Morabito10, Yana Najjar5, Paul Nathan11, Kunle Odunsi12, Akash Patnaik13, Chrystal M Paulos14, Bradley I Reinfeld15, Heath D Skinner16, John Timmerman17, Igor Puzanov18.
Abstract
Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4-5 December, 2019, Naples, Italy), and are summarised in this report.Entities:
Keywords: Biomarkers; Checkpoint inhibitors; Combination therapy; Immunotherapy; Tumor microenvironment; Vaccine
Mesh：
Substances：
Year: 2021 PMID： 33407605 PMCID： PMC7789268 DOI： 10.1186/s12967-020-02627-y
Source DB: PubMed Journal: J Transl Med ISSN： 1479-5876 Impact factor: 5.531